《慢性乙型肝炎防治指南(2022年版)》解读  

Interpretation of guidelines for the prevention and treatment of chronic hepatitis B(2022 edition)

作　　者：谢艳迪[1] 封波[1] 饶慧瑛[1] XIE Yandi;FENG Bo;RAO Huiying(Peking University People’s Hospital,Peking University Hepatology Institute,Beijing 100044,China)

机构地区：[1]北京大学人民医院,北京大学肝病研究所,北京100044

出　　处：《临床肝胆病杂志》2023年第7期1553-1559,共7页Journal of Clinical Hepatology

摘　　要：《慢性乙型肝炎防治指南(2022年版)》是以国内外慢性HBV感染的研究进展为依据,在既往多版指南基础上进行更新和修订而成。本文介绍了新版指南在自然史、无创纤维化诊断、治疗等多方面的更新内容。尤其是进一步扩大了慢性HBV感染者的治疗适应证,对干扰素的优势人群选择限定更清晰,对口服核苷(酸)类似物标准进行了更严格限制,对低病毒血症患者的处理更加积极,对免疫耐受期儿童的治疗也更积极。新版指南将为我国扩大筛查HBV感染者、提高诊断率、优化治疗方案、规范临床管理提供重要依据。Guidelines for the prevention and treatment of chronic hepatitis B(2022 edition)are updated and revised based on the research advances in chronic hepatitis B virus infection in China and globally and the previous editions of the guidelines.This article introduces the updates in natural history and the noninvasive diagnosis and treatment of fibrosis.In particular,the guidelines further expand the indications for patients with chronic hepatitis B virus infection,clearly defines the selection of the population benefiting from interferon therapy,and strictly limits the standard of oral nucleos(t)ide analogues.Meanwhile,the guidelines also recommend more active treatment of patients with low-level viremia and children in the immune-tolerant phase.The new edition of the guidelines will provide an important basis for expanding the screening for hepatitis B virus infection,improving diagnostic rate,optimizing treatment regimens,and standardizing clinical management in China.

关 键 词：乙型肝炎 慢性 乙型肝炎病毒 诊疗准则 

分 类 号：R512.62[医药卫生—内科学]